HR+, HER2-, ADVANCED BREAST CANCER
Clinical trials for HR+, HER2-, ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+, HER2-, ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+, HER2-, ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on tough breast cancers
Disease control Recruiting nowThis study is testing a new combination of two drugs for people with advanced breast cancer that has spread and is hard to treat. The main goals are to see if the combination is safe and if it can shrink or control the cancer. It will enroll about 50 people with specific types of…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New pill targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis is the first study in people for a new oral medication called AVZO-021. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain types of breast and ovarian cancer, when other standard treatments are no longer working. The stu…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New pill targets advanced breast cancer in First-Ever human trial
Disease control Recruiting nowThis is the first human study testing a new oral medication called AVZO-023 for patients with advanced solid tumors, focusing on a common type of breast cancer. The trial aims to find the safest and most effective dose, first by giving AVZO-023 alone, and then in combination with…
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:21 UTC
-
New hope for advanced breast cancer patients with specific gene mutation
Disease control AVAILABLEThis program provides access to the drug alpelisib for adults with advanced hormone-positive, HER2-negative breast cancer that has a specific genetic mutation (PIK3CA) and has progressed after standard hormone therapy. It's designed for patients who meet specific health criteria …
Matched conditions: HR+, HER2-, ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jan 13, 2026 15:13 UTC